By Jonathan Smith at Labiotech.eu Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and
Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB) Clinical trial preparations of OMN6 under way Jerusalem, Israel — Omnix Medical, a Jerusalem-based biopharmaceutical
New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we
Une nouvelle technologie inspirée par la nature pour éradiquer de dangereuses bactéries multirésistantes. (A new technology inspired by nature to eradicate dangerous multiresistant bacteria.)
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme.
Omnix Medical, a Jerusalem-based biopharmaceutical company, has completed an $8.5 million round led by Tal Capital (US) and Entrée Capital (IL) in association with UK based businessman Vincent Chenkwiz of CBG Group (UK) and joined by Xenia Ventures (IL) VLX Ventures (IL) and the Israeli Innovation Authority (IIA). Since its inception, the company has raised $10M.
Omnix Medical, a biotech company dedicated to the development of novel antimicrobial pharmaceuticals against drug-resistant bacteria, today announced the appointment of Antonius (Toni) Schuh, Ph.D.,
Offering new hope for patients suffering from drug resistant infections SAN FRANCISCO, Calif., January 3, 2020 – Omnix Medical has scheduled a company presentation at